Integrating Metabolism and Tumor Biology joint with PI 3-Kinase Signaling Pathways in Disease Organizer(s): Ralph J. DeBerardinis, Robert T. Abraham and Eyal Gottlieb Date: January 13 - 18, 2015
Location: Fairmont Hotel Vancouver, Vancouver, BC, CanadaWork in recent years has demonstrated extensive interconnectivity between oncogenic signaling pathways and intermediate metabolism. Compelling evidence indicates that signaling aberrations that drive oncogenesis trigger extensive alterations in metabolic flux; conversely, mutational alterations in certain metabolic enzymes are capable of priming cells for malignancy. These observations have raised hopes that understanding the metabolic underpinnings of cellular transformation, tumor growth and metastasis will result in more effective strategies to diagnose and treat cancer. Current challenges include understanding how best to translate observations from simple models of tumor cell growth to bona fide tumors in vivo, and understanding which aspects of dysregulated cell metabolism contribute to tumor maintenance and progression. This conference will bring together scientists from academia and industry attacking this problem on many levels. A major theme of the meeting will be exploring the cross-talk between metabolism and various other dimensions of systems biology, including epigenetics, protein function, stress responses and signal transduction. Emerging principles regarding the influence of the tumor microenvironment on cellular metabolism will be discussed in detail, as will new progress toward exploiting metabolic reprogramming to image and treat cancer. The meeting is paired with one on “PI 3-Kinase Signaling Pathways in Disease,” providing a fertile environment for exchange of ideas between these two highly connected fields. Scholarship Deadline: September 24 2014 Discounted Abstract Deadline: September 24 2014 Abstract Deadline: October 16 2014 Discounted Registration Deadline: November 13 2014 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
GlaxoSmithKline
Pfizer Global Research & Development
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:  We gratefully acknowledge the generous grant for this conference provided by: National Cancer Institute (NCI)Grant No. 1R13CA189443-01 Funding for this conference was made possible (in part) by 1R13CA189443-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |